426 related articles for article (PubMed ID: 25645206)
1. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.
Lahiri SD; Walkup GK; Whiteaker JD; Palmer T; McCormack K; Tanudra MA; Nash TJ; Thresher J; Johnstone MR; Hajec L; Livchak S; McLaughlin RE; Alm RA
J Antimicrob Chemother; 2015; 70(6):1650-8. PubMed ID: 25645206
[TBL] [Abstract][Full Text] [Related]
2. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
[TBL] [Abstract][Full Text] [Related]
3. Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC-producing Enterobacteriaceae.
Livermore DM; Mushtaq S; Doumith M; Jamrozy D; Nichols WW; Woodford N
J Antimicrob Chemother; 2018 Dec; 73(12):3336-3345. PubMed ID: 30247546
[TBL] [Abstract][Full Text] [Related]
4. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
6.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
7. Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme.
Lahiri SD; Giacobbe RA; Johnstone MR; Alm RA
J Antimicrob Chemother; 2014 Nov; 69(11):2942-6. PubMed ID: 24986496
[TBL] [Abstract][Full Text] [Related]
8. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Pitart C; Marco F; Keating TA; Nichols WW; Vila J
Antimicrob Agents Chemother; 2015; 59(6):3059-65. PubMed ID: 25753646
[TBL] [Abstract][Full Text] [Related]
9. Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.
Castanheira M; Doyle TB; Smith CJ; Mendes RE; Sader HS
J Antimicrob Chemother; 2019 Sep; 74(9):2588-2595. PubMed ID: 31225882
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa.
Buyck JM; Luyckx C; Muccioli GG; Krause KM; Nichols WW; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2017 May; 72(5):1400-1409. PubMed ID: 28137941
[TBL] [Abstract][Full Text] [Related]
11. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Berrazeg M; Jeannot K; Ntsogo Enguéné VY; Broutin I; Loeffert S; Fournier D; Plésiat P
Antimicrob Agents Chemother; 2015 Oct; 59(10):6248-55. PubMed ID: 26248364
[TBL] [Abstract][Full Text] [Related]
12. Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam.
Slater CL; Winogrodzki J; Fraile-Ribot PA; Oliver A; Khajehpour M; Mark BL
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660987
[No Abstract] [Full Text] [Related]
13. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).
Livermore DM; Mushtaq S; Barker K; Hope R; Warner M; Woodford N
J Antimicrob Chemother; 2012 Jun; 67(6):1354-8. PubMed ID: 22441578
[TBL] [Abstract][Full Text] [Related]
14.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
[TBL] [Abstract][Full Text] [Related]
15. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
[TBL] [Abstract][Full Text] [Related]
16. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
Winkler ML; Papp-Wallace KM; Bonomo RA
J Antimicrob Chemother; 2015 Aug; 70(8):2279-86. PubMed ID: 25957381
[TBL] [Abstract][Full Text] [Related]
17. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-Avibactam Resistance Mediated by the N
Compain F; Debray A; Adjadj P; Dorchêne D; Arthur M
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253219
[TBL] [Abstract][Full Text] [Related]
20. Molecular Basis of AmpC β-Lactamase Induction by Avibactam in
López-Argüello S; Montaner M; Oliver A; Moya B
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
